A novel ERBB4 agonist attenuates cardiac remodelling after myocardial infarction in a sex-specific manner

Back

HFA Premium Access

A novel ERBB4 agonist attenuates cardiac remodelling after myocardial infarction in a sex-specific manner

Session: Tailoring heart failure therapies on patient profiles

Topic: Pharmacotherapy

Speaker: Miss B. Goovaerts (Antwerp, BE)

Event: Heart Failure 2024

Congress Presentation

Add to my library

About the speaker

Miss Bo Goovaerts

University of Antwerp, Antwerp (Belgium)

0 follower

6 more presentations in this session

Effect of intravenous ferric derisomaltose on outcomes in heart failure with or without ischaemic heart disease in the IRONMAN trial.

Speaker: Professor J. Cleland (Glasgow, GB)

Sex differences in the prognostic role of achieving target doses of heart failure with reduced ejection fraction medications: data from the Swedish Heart Failure Registry

Speaker: Doctor D. Stolfo (Trieste, IT)

Phenotyping of patients with chronic obstructive pulmonary disease and heart failure: data from the swedish heart failure registry

Speaker: Assistant Professor P. Becher (Hamburg, DE)

Sotagliflozin is effective in reducing heart failure risk of events in patients with HFpEF

Speaker: Doctor M. Davies (The Woodlands, US)

Combined treatment with SGLT2i and GLP1ra compared with SGLT2i or GLP1ra alone improves survival: a Real-World Registry

Speaker: Doctor D. Garcia Vega (Santiago de Compostela, ES)

Access the full session

Tailoring heart failure therapies on patient profiles

Speakers: Miss B. Goovaerts, Professor J. Cleland, Doctor D. Stolfo, Assistant Professor P. Becher, Doctor M. Davies...

Access

Video

About the event

Heart Failure 2024

11 May - 14 May 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources